SCHEMBL2270359

SCHEMBL2270359

O=C(Nc1cc(-c2ccccc2F)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
PKM P14618 2/20 0.57
MAPT P10636 2/20 0.57
GRIK1 P39086 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
ACMSD Q8TDX5 1/20 0.56
ACLY P53396 3/20 0.55
DHODH Q02127 1/20 0.54
HDAC2 Q92769 2/20 0.50
RAB9A P51151 2/20 0.50
SERPINE1 P05121 1/20 0.50
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPC1 O15118 1/20 0.50
HDAC1 Q13547 3/20 0.49
HTT P42858 1/20 0.48
KDM4D Q6B0I6 1/20 0.48
KDM4C Q9H3R0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270510 0.91 MEN1 (0.54) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2274304 0.88 ACLY (0.55) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2270444 0.88 MEN1 (0.54) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2270946 0.87 SERPINE1 (0.62) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2276831 0.86 ACLY (0.59) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2270516 0.85 ACLY (0.64) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2276609 0.85 PKM (0.59) MEN1KMT2APKMMAPTGRIK1
SCHEMBL1319364 0.85 ACLY (0.52) ACMSDACLYDHODHHDAC2SERPINE1
SCHEMBL1317189 0.84 ACLY (0.51) ACMSDACLYDHODHHDAC2SERPINE1
SCHEMBL2270787 0.84 MEN1 (0.57) MEN1KMT2APKMMAPTGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.